{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=2", "query": { "intervention": "Placebo Intravenous", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 2346, "total_pages": 235, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T23:26:58.950Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04295538", "title": "Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Spinal Cord Injury (SCI)" ], "interventions": [ { "name": "Elezanumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 60, "start_date": "2020-09-06", "completion_date": "2026-01-26", "has_results": false, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-09-30T23:26:58.950Z", "location_count": 22, "location_summary": "Sacramento, California • Atlanta, Georgia • Chicago, Illinois + 15 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04295538" }, { "nct_id": "NCT01544348", "title": "A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Allergic Asthma", "Atopic Dermatitis", "Allergic Rhinitis", "Healthy Volunteers" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Omalizumab", "type": "BIOLOGICAL" }, { "name": "MEDI4212 5 mg Subcutaneous", "type": "BIOLOGICAL" }, { "name": "MEDI4212 15 mg Subcutaneous", "type": "BIOLOGICAL" }, { "name": "MEDI4212 60 mg Subcutaneous", "type": "BIOLOGICAL" }, { "name": "MEDI4212 150 mg Subcutaneous", "type": "BIOLOGICAL" }, { "name": "MEDI4212 300 mg Subcutaneous", "type": "BIOLOGICAL" }, { "name": "MEDI4212 300 mg Intravenous", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 295, "start_date": "2012-01", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2014-12-30", "last_synced_at": "2026-09-30T23:26:58.950Z", "location_count": 7, "location_summary": "Cypress, California • Glendale, California • Denver, Colorado + 4 more", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01544348" }, { "nct_id": "NCT00361335", "title": "A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Golimumab", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centocor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 643, "start_date": "2006-09", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2014-07-29", "last_synced_at": "2026-09-30T23:26:58.950Z", "location_count": 20, "location_summary": "Peoria, Arizona • Aventura, Florida • Orlando, Florida + 17 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Aventura", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00361335" }, { "nct_id": "NCT01643850", "title": "MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pigmented Villonodular Synovitis", "PVNS", "Giant Cell Tumor of the Tendon Sheath", "GCCTS", "Tenosynovial Giant Cell Tumor Localized or Diffused Type", "GCTS" ], "interventions": [ { "name": "MCS110", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 36, "start_date": "2012-04-23", "completion_date": "2018-12-21", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-09-30T23:26:58.950Z", "location_count": 7, "location_summary": "San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01643850" }, { "nct_id": "NCT07167693", "title": "Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diabetes (DM)", "Diabetic Ketoacidosis", "Ketosis Prone Diabetes", "Hyperglycaemia (Diabetic)" ], "interventions": [ { "name": "Arginine hydrochloride", "type": "DRUG" }, { "name": "Sodium Chloride 0.9%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David K Carroll", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-12-19", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-09-30T23:26:58.950Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07167693" }, { "nct_id": "NCT05547438", "title": "Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Ischemic Stroke" ], "interventions": [ { "name": "NTS-104 TRIS", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NeuroTrauma Sciences, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2023-05-01", "completion_date": "2026-01-08", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-30T23:26:58.950Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05547438" }, { "nct_id": "NCT03094442", "title": "Does Dexamethasone Administration Improve Recovery In Patients Undergoing Minimally Invasive Sacrocolpopexy?", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Quality of Life", "Pelvic Organ Prolapse", "Prolapses, Vaginal Vault" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Normal saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2016-12", "completion_date": "2019-12", "has_results": false, "last_update_posted_date": "2020-02-05", "last_synced_at": "2026-09-30T23:26:58.950Z", "location_count": 1, "location_summary": "Weston, Florida", "locations": [ { "city": "Weston", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03094442" }, { "nct_id": "NCT02377466", "title": "A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Obstetric Labour, Premature" ], "interventions": [ { "name": "Retosiban IV infusion", "type": "DRUG" }, { "name": "Placebo IV infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "12 Years to 45 Years · Female only" }, "enrollment_count": 25, "start_date": "2016-02-29", "completion_date": "2017-07-24", "has_results": true, "last_update_posted_date": "2020-07-28", "last_synced_at": "2026-09-30T23:26:58.950Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Colton", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02377466" }, { "nct_id": "NCT04355767", "title": "Convalescent Plasma in Outpatients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "Convalescent Plasma", "type": "BIOLOGICAL" }, { "name": "Saline", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 511, "start_date": "2020-08-11", "completion_date": "2021-03-29", "has_results": true, "last_update_posted_date": "2021-10-19", "last_synced_at": "2026-09-30T23:26:58.950Z", "location_count": 53, "location_summary": "Chandler, Arizona • Phoenix, Arizona • La Jolla, California + 41 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04355767" }, { "nct_id": "NCT00091507", "title": "IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Angina, Unstable", "Cardiovascular Diseases", "Heart Diseases", "Coronary Disease", "Myocardial Infarction", "Heart Failure, Congestive" ], "interventions": [ { "name": "GIK", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tufts Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 911, "start_date": "2006-11", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2016-03-02", "last_synced_at": "2026-09-30T23:26:58.950Z", "location_count": 13, "location_summary": "Anchorage, Alaska • New Haven, Connecticut • Macon, Georgia + 10 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Macon", "state": "Georgia" }, { "city": "Brockton", "state": "Massachusetts" }, { "city": "Concord", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00091507" } ] }